Related Experiment Video
Updated: Jul 17, 2026

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
Published on: December 8, 2014
Pseudomembranous colitis following bortezomib therapy in a myeloma patient
Sung-Jin Moon1, Chang-Ki Min, Dong-Gun Lee
1Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Abstract:
The proteasome inhibitor, bortezomib, has antimyeloma activity even in myeloma cells refractory to multiple prior treatments. The most commonly reported adverse events in patients receiving bortezomib are sensory neuropathy, thrombocytopenia and gastrointestinal events. We report a patient with myeloma who developed pseudomembranous colitis after bortezomib treatment. Bortezomib has the boronic acid moiety which improves the specificity of proteasome inhibition and can be used as non-beta-lactam-based beta-lactamase inhibitors. This case indicates that gastrointestinal toxicities by bortezomib may be caused, in part, as a result of change in the colonization of colonic microflora.
Related Concept Videos
Diverticular Disease of the Colon
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease IV: Clinical Manifestations
Inflammatory Bowel Disease II: Ulcerative Colitis
